New study shows species-specific ‘shedding’ could distort efficacy of cancer drugs targeting TIGIT
Peer-Reviewed Publication
Updates every hour. Last Updated: 10-Dec-2025 17:11 ET (10-Dec-2025 22:11 GMT/UTC)
Anti-TIGIT immunotherapy drugs behave differently in macaques and humans. The findings may explain why immunotherapy anti-TIGIT antibodies have failed in Phase III trials.
Lehigh University researcher Hannah Dailey is leading a new international collaboration to improve predictions of how bone fractures heal. Supported by the U.S. National Science Foundation and the Swiss National Science Foundation, the four-year project partners with the AO Research Institute Davos (ARI) to develop computational models that combine mechanical factors—such as implant stiffness and loading patterns—with biological processes that vary from patient to patient. Using ARI’s extensive imaging library documenting fracture healing in sheep, the team will build probabilistic models capable of forecasting how recovery will progress. The models will ultimately be integrated into ARI’s online training platform to help surgeons understand how implant choices and rehabilitation strategies influence healing. Long term, the goal is to enable patient-specific simulations that help clinicians identify complications earlier and make more informed treatment decisions.
Primary pulmonary nuclear protein of the testis (NUT) midline carcinoma (NMC) is an extremely rare, highly aggressive thoracic malignancy that presents significant diagnostic and therapeutic challenges, characterized by heterogeneous clinical manifestations, frequent misdiagnosis, and a poor prognosis. This case report details two patients with advanced primary pulmonary NMC treated with a multimodal strategy combining anti-angiogenic agents, platinum-based chemotherapy, and radiotherapy—achieving overall survival (OS) of 32 and 13 months, respectively, which far exceeds the currently reported median OS of approximately 6.7 months for advanced NMC. A systematic literature review of 86 published cases (2011–2024) was also conducted, summarizing current diagnostic methods (such as immunohistochemistry for nuclear NUT expression and fluorescence in situ hybridization (FISH) for NUTM1 rearrangement) and treatment modalities for NMC. Findings indicate that multimodal therapy incorporating anti-angiogenic agents yields superior clinical outcomes compared to conventional monotherapy, especially for patients ineligible for surgery. The report also highlights diagnostic pitfalls, such as overlapping histopathological features with squamous cell carcinoma, and underscores how integrating anti-angiogenic therapy addresses the aggressive biology of NMC, offering a new therapeutic direction for this refractory malignancy.